Pharma is Exploiting the Poorest Among Us to get FDA Approval
and Reap Billions in Drug RevenuesPharma loves to test drugs on the most vulnerable among us: these folks need the money, and they often push aside worries about the potential 'side effects' because they have more critical immediate needs, including food, shelter, clothing and other survival needs. The money they receive for being guineapigs for the pharmaceutical companies is 'here and now' - and the potential long-term consequences are not part of the decision-making process.
This vulnerability is a perfect setup for Pharma's clinical trials of large groups of people. The drug companies need large groups of experimental subjects, and - for a few dollars each - it will be well worth the investment, as they run the studies required for FDA approval, and look forward to earning billions in revenues.
The Swine Flu Vaccine trials may well be among the worst ethical and potentially deadly offenses in history. The pharmaceutical Industry has been indemnified from legal repercussions if/when the vaccines hurt people. The FDA is also indemnified; they can't be sued for non-existent oversight of Pharma. In the end, the test subjects will suffer; the studies will be done, and people will be vaccinated BEFORE adequate test data on effectiveness and adverse reactions becomes available. In short, the Government and Pharma have carte blanche to deliver vaccines UNTESTED to a worldwide population.
Examples, recent and historical, of Pharma using vulnerable test subjects:Volunteers swarm for shot at swine flu vaccinehttp://www.newsvine.com/_news/2009/07/29/3086547-volunteers-swarm-for-shot-at-swine-flu-vaccine.... Hankins said she was told she and her family members would be paid $50 apiece for each of the three or four visits they expect to make to the clinic....
Testing new drugs on the world’s poorhttp://www.global-sisterhood-network.org/content/view/1800/59/Urgency Tempers Ethics Concerns in Uganda Trial of AIDS Vaccine http://www.michaelspecter.com/times/1998/1998_10_01_nyt_aids.htmlAIDS Vaccine Testing Goes Overseashttp://www.redorbit.com/news/health/666750/aids_vaccine_testing_goes_overseas/index.html?source=r_healthHas the race to save Africa from aids put Western science at odds with Western ethics?http://www.michaelspecter.com/ny/2003/2003_02_03_vaccine.htmlDisclosure of Financial Relationships to Participants in Clinical Researchhttp://content.nejm.org/cgi/content/full/361/9/916Kevin P. Weinfurt, Ph.D., Mark A. Hall, J.D., Nancy M.P. King, J.D., Joëlle Y. Friedman, M.P.A., Kevin A. Schulman, M.D., and Jeremy Sugarman, M.D., M.P.H.
In keeping with previous statements by a number of prominent groups,
1,2,3,4 the Institute of Medicine has recently stressed the need for vigilance in managing conflicts of interest to ensure the integrity of clinical research.
5 The Institute of Medicine adopts a position similar to that of the Association of American Medical Colleges
1 — that is, it assumes that there is a rebuttable presumption of a conflict of interest if the investigator has a financial interest in the outcome of research that involves human subjects. Although the institute's report emphasizes the need for disclosure of financial interests to institutions and peer reviewers, it differs from many of the earlier guidelines in that it stresses the need to limit researchers' financial interests more than the need to disclose such interests to research participants.
Nevertheless, at times such disclosures may be called for. In some cases, the relevant institutional body will conclude that a potential conflict of interest is tolerable. In others, it might view a financial relationship as not posing any conflict of interest (e.g., the study sponsor's paying an investigator for the costs of conducting a study). Finally, bans on financial relationships with trial sponsors are only recommended, not required, so some institutions might still allow them. In all three of these circumstances, it may be reasonable to expect that — at a minimum — disclosure to the research subjects would be required.
Sound management of conflicts of interest should be based on clear policy goals and, whenever possible, rely on valid empirical data.
6 To help researchers better understand the proper role of disclosure to trial participants as one of several techniques for managing conflicts of interest, we draw on 5 years of empirical data from the Conflict of Interest Notification Study, which was supported by the National Institutes of Health, as well as from other research findings, to formulate six suggested goals of disclosure.
Goals of DisclosurePolicymakers and officials charged with oversight of human subjects may consider several different goals when deciding whether to require that financial relationships be disclosed to potential research participants. We discuss six possible goals of such disclosures (Table 1).
Table 1. Potential Goals and Challenges of Disclosing Financial Relationships in Clinical Research.
Promoting Informed Decision MakingDisclosures to research participants during the informed-consent process are meant to promote autonomous decision making.
7,8,9 What exactly constitutes an autonomous decision by the participant is a matter of debate, but most experts describe it as a choice made after the person has gained a substantial understanding of the potential risks and benefits of enrollment.
Studies have identified at least four major challenges to achieving a substantial understanding of financial relationships in clinical research. First, there is wide variation in views and practice about what to tell participants about a researcher's financial relationships.
9,10,11,12,13 A typical disclosure statement identifies the possibility of a bad clinical outcome, usually based on data from preliminary studies in animals or humans. Financial disclosures present two principal risks: harm to the research participants and harm to the study's scientific integrity (e.g., the investigator might be biased in interpreting the results). These risks are more difficult to estimate than medical risks, because we lack data for estimating the risks and also for explaining how an investigator's financial relationships might best inform a participant's decision whether to enroll in a trial.
Another challenge is that many people have trouble understanding the nature and implications of financial relationships in clinical research. For example, in focus groups, some participants remained confused about certain financial interests — especially equity interests — even after 2 hours of discussion.
14 Others mentioned that before the focus group, they would not have known what to ask about such relationships if given the opportunity — both because they might not have understood the information and because they might not have considered these relationships important. If people do not understand a topic well enough to ask questions, they will find it difficult to reach a substantial understanding. These problems are also probably exacerbated by the daunting length and complexity of many consent documents.
A third challenge is the possibility that disclosure will paradoxically reinforce a "therapeutic misconception" — namely, blurring the distinction between clinical care and clinical research.
15,16,17 Data suggest that some people place more faith in an experimental intervention when the investigator has a financial stake in the product being tested, believing that the investigator's investments signal his or her confidence in the product.
14 The failure to comprehend the risks associated with financial interests raises questions about whether financial disclosures contribute positively or negatively to informed decision making.
Finally, study coordinators, who are frequently charged with obtaining consent, often lack the information they need about investigators' financial relationships. In one survey, over 75% of study coordinators cited this deficit as the primary barrier to addressing participants' questions about conflicts of interest.
18 These four challenges make it difficult for disclosures of financial interests to promote the informed and substantial understanding that should be the basis for a participant's autonomous decision about whether to enroll in a clinical trial. As the Institute of Medicine concluded,
5 "it is not clear that it is reasonable to expect the average participant to understand these issues." Nevertheless, financial disclosures clearly make a difference in some people's decisions, especially when equity relationships are involved. For example, in our study of 470 cardiac patients, 5% of those who were told about a hypothetical investigator's equity interest said they would not participate for that reason alone.
19 Yet other financial interests (e.g., per capita payments from sponsors to investigators) do not seem to generate concern, suggesting that such information could be made more prominent or accessible to improve a participant's understanding of the role such interests might play in the conduct of the research.
Highlighting an investigator's financial relationships, however, might inappropriately increase their salience relative to other, more important information in the consent document.
9 If the information about financial interests does not in fact represent a tangible risk, presenting it as such could be misleading or could detract from aspects of the study that are more germane to informed decision making. Although a major concern has been that placing too much importance on a researcher's financial interests will cause potential study subjects to decline to participate,9 this concern is not borne out by the available data. Several studies that have used different methods of data collection consistently showed that in most cases an investigator's financial disclosures did not dampen subjects' willingness to participate in research studies.
19,20,21,22,23 This is not to say, however, that financial disclosures do not matter at all.
Respecting Participants' Perceived Right to KnowData from multiple studies confirm that most research participants want to know about the investigators' financial relationships, even though this information may not affect their enrollment decision.
14,22 Some potential study subjects report that they would be angry if they learned about such a relationship after the fact. In other words, they might feel morally wronged by an investigator's failure to disclose his or her personal financial interests in a trial. Nevertheless, in two large studies that examined enrollment decisions in hypothetical clinical trials, most respondents rated financial disclosure as the least important factor in their decision about whether to participate.
19,23 This simple right to know could be seen as a question of materiality. A basic tenet of the informed-consent process is that information considered to be material to a decision must be disclosed.[sup]24[/sup] For some people, information can be deemed material even if it would not change the decision, although others disagree.25 Potential participants consistently express a desire to be informed about financial interests in clinical studies on the part of the institutions or investigators conducting the research.
14,22 However, there are methodologic challenges to finding out what patients really want disclosed. The artificial setting and the manner in which people are asked about their preferences for disclosure might affect their answers (e.g., failing to show how the length of a consent form would change if all the information the participant requested was disclosed in full detail). Moreover, some participants might give what they judge to be a socially desirable response rather than express their sincere preference for disclosure. If these responses are used to determine the content of disclosure, consent forms might become overloaded with disclosures of all conceivable benefits and harms, regardless of their likelihood. As already noted, the link between financial relationships and risks of harm, though undoubtedly of concern to study participants, is tenuous and difficult to estimate at best.
Establishing or Maintaining TrustAnother goal of disclosure is to establish or maintain the trust of study participants.
1,26 In the literature, many statements about trust are normative claims about what merits trust (i.e., trustworthiness) rather than empirical reports of the actual determinants of trust.
27 In the context of clinical research, the question of trustworthiness is separable from the question of whether in fact the research enterprise is trusted. Empirically, disclosing financial relationships may promote or decrease trust.
14,28 Findings depend on the type of financial relationship disclosed. In many cases, such as per capita payments by study sponsors to investigators, disclosure is associated with sustained or slightly increased trust, whereas the disclosure of equity relationships with sponsors has been associated with slightly decreased trust.
14,19,23 Findings also vary according to the object of trust. Trust is greatest for research institutions, moderate for researchers, and lowest for pharmaceutical companies.19 Overall, it appears that, for most financial interests in research, the disclosures tested so far do not undermine trust and may even help to improve or sustain trust to a moderate extent. However, equity relationships are more worrisome than are other financial relationships.
Minimizing Risk of Legal LiabilityMany lawyers and administrators believe that disclosing financial relationships will help limit legal liability. Yet experience to date suggests that disclosure may be neither necessary nor sufficient for legal protection. There are two competing legal views. According to one view, disclosure of financial interests is necessary to avoid violating an investigator's (or institution's) fiduciary duty to act in good faith to protect the interests of a research participant.
29,30 The alternative view is that the fiduciary duty applicable to clinical treatment does not apply to research settings
31,32; even if it did,
some courts hold that there is no breach of fiduciary duty or informed consent by failing to disclose information about the clinician, in contrast to information about the treatment.
25 Thus, in some states there may be
no liability risk for failing to disclose financial relationships. Even if there is such a risk, there is no precedent for determining whether a particular disclosure is sufficiently thorough. Instead, the lesson from the clinical trial involving gene transfer in which Jesse Gelsinger died is that lawsuits can result in substantial financial settlements even when a disclosure has been made.
33 Moreover, consent forms should not be regarded primarily as documents that can be used to shift or waive legal risks. This view makes neither legal nor moral sense. If harm that can be linked to financial entanglements were to occur, a disclosure of those entanglements might make a lawyer's defense somewhat easier, but it is hard to imagine that such a disclosure would entirely obviate the investigator's or institution's legal and moral responsibility to minimize harm to research subjects.
Deterring Troubling Financial RelationshipsThis fifth goal assumes that investigators dislike having to disclose their financial interests in a trial and will avoid relationships that might suggest a conflict of interest.
34 At present, there are no data to support this particular claim. However, research in other contexts has illuminated possible psychological effects on the person making the disclosure. Some of the findings are troubling and reveal that professionals might in some cases view compliance with disclosure as a moral license to follow their self-interest.
35,36 Thus, by laying their cards on the table, investigators might adopt an attitude of caveat emptor and become less vigilant in policing their own judgmental biases with regard to enrolling patients, collecting data, interpreting results, and other research activities. These findings stand in sharp contrast both to the legal view of disclosure, as described above, and to an understanding of the consent process as a beneficial exchange of information between investigator and participant.
37 Protecting Research Participants' WelfareThe final goal of disclosure is the most basic: to protect the welfare of research participants. This goal implies that some financial relationships could increase the risk of harm to the study subjects, although there is no systematic evidence of such a connection in the research setting. If there were, any protection from disclosure would come only as a result of either deterring investigators from entering dangerous financial relationships or improving informed decision making.
Conclusions and RecommendationsOn the basis of the evidence to date, we offer the following recommendations to investigators, institutional review boards, conflict-of-interest committees, and policymakers. First, study participants should not be the sole decision makers with respect to the acceptable risks of investigators' financial relationships in clinical research. At the very least, institutional review boards and officials charged with research oversight should play a significant role in determining the acceptability of these relationships. Many participants do not have the requisite understanding of clinical studies, investigators' responsibilities, or the nature and potential effects of financial incentives.
Second, disclosure during the consent process should be brief and simple and should allow participants to ask questions. Even though they may not fully understand the implications of financial disclosure, such a dialogue encourages transparency, satisfies many participants' perceived right to know, and may foster trust in research in general.
Third, research participants are sometimes troubled by investigators' equity interests in clinical research. Attempting to manage equity relationships through disclosure to participants is problematic, in part because this type of financial stake seems to have greater potential to reinforce a therapeutic misconception than do other relationships. Therefore, an investigator's equity interests should be limited, if not avoided, rather than simply disclosed.
Fourth, study coordinators and other personnel involved in obtaining informed consent should receive the information and training they need to address questions posed by potential subjects concerning investigators' or institutions' financial relationships.
Fifth, those charged with overseeing potential conflicts of interest in research should be explicit about the goals they hope to achieve and should design disclosure statements accordingly to meet those goals.
The Institute of Medicine's recent report will not put an end to the considerable controversy and policymaking that surround physicians' and medical institutions' possible financial conflicts of interest.
5,38,39,40,41,42,43 However, as this overview has attempted to show, it was correct to conclude that disclosure is not the remedy that many seek. Still, disclosure may have positive effects on people's satisfaction with and trust in the research process. As the Institute of Medicine recommends, a coordinated research agenda is needed to craft more effective approaches to managing conflicts of interest.
5 It is important that this agenda distinguish among the various goals of disclosure that we have enumerated. Only in this way can focused empirical studies generate useful data to help us understand the effects and limitations of various policies addressing the oversight and management of financial relationships in clinical research.
Supported by a grant from the National Heart, Lung, and Blood Institute (R01HL075538). Dr. Weinfurt reports receiving research support from Bristol-Myers Squibb and Inspire Pharmaceuticals and consulting fees from Inspire Pharmaceuticals; a detailed listing of Dr. Weinfurt's financial disclosures is available online (
www.dcri.duke.edu/research/coi.jsp).
Dr. Schulman reports receiving research support from Actelion Pharmaceuticals, Allergan, Amgen, Astellas Pharma, Bristol-Myers Squibb, Inspire Pharmaceuticals, Medtronic, NovaCardia, Novartis, OSI Eyetech, Tengion, Theravance, Thomson Healthcare, and Vertex Pharmaceuticals; receiving consulting fees from the National Pharmaceutical Council; having equity in Alnylam Pharmaceuticals; having equity in and serving on the board of directors of Cancer Consultants; and having equity in and serving on the executive board of Faculty Connection; a detailed listing of Dr. Schulman's financial disclosures is available online (
www.dcri.duke.edu/research/coi.jsp).
No other potential conflict of interest relevant to this article was reported.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.
We thank N. Chantelle Hardy, Michaela A. Dinan, Jatinder K. Dhillon, Jennifer S. Allsbrook, Alice K. Fortune-Greeley, and Janice S. Lawlor for research assistance, and Damon M. Seils for assistance with manuscript preparation.
Source InformationFrom the Center for Clinical and Genetic Economics, Duke Clinical Research Institute (K.P.W., J.Y.F., K.A.S.), and the Departments of Psychiatry and Behavioral Sciences (K.P.W.) and Medicine (K.A.S.), Duke University School of Medicine, Durham, NC; Wake Forest University Center for Bioethics, Health, and Society and the Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine (M.A.H., N.M.P.K.) — both in Winston-Salem, NC; and the Berman Institute of Bioethics and the Department of Medicine, Johns Hopkins University, Baltimore (J.S.).
Address reprint requests to Dr. Sugarman at the Berman Institute of Bioethics, Johns Hopkins University, Hampton House 351, 624 N. Broadway, Baltimore, MD 21205, or to
jsugarm1@jhmi.edu.
References1. AAMC Task Force on Financial Conflicts of Interest in Clinical Research. Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research. Acad Med 2003;78:237-245. [Web of Science][Medline]
2. Protecting patients, preserving integrity, advancing health: accelerating the implementation of COI policies in human subjects research. Washington, DC: Association of American Medical Colleges, 2008.
3. The Food and Drug Administration's oversight of clinical investigators' financial information. Washington, DC: Department of Health and Human Services, 2009. (DHHS publication no. OEI-05-07-00730.)
4. Morin K, Rakatansky H, Riddick FA Jr, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA 2002;287:78-84. [Free Full Text]
5. Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, DC: National Academies Press, 2009.
6. Lavori PW, Sugarman J, Hays MT, Feussner JR. Improving informed consent in clinical trials: a duty to experiment. Control Clin Trials 1999;20:187-193. [CrossRef][Web of Science][Medline]
7. Faden RR, Beauchamp TL. Decision-making and informed consent: a study of the impact of disclosed information. Soc Indic Res 1980;7:313-336. [CrossRef][Web of Science][Medline]
8. Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th ed. Oxford, England: Oxford University Press, 2001.
9. Weinfurt KP, Friedman JY, Dinan MA, et al. Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. J Law Med Ethics 2006;34:581-591. [Free Full Text]
10. Weinfurt KP, Dinan MA, Allsbrook JS, et al. Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants. Acad Med 2006;81:113-118. [CrossRef][Web of Science][Medline]
11. Lipton S, Boyd EA, Bero LA. Conflicts of interest in academic research: policies, processes, and attitudes. Account Res 2004;11:83-102. [Medline]
12. Weissman JS, Koski G, Vogeli C, Thiessen C, Campbell EG. Opinions of IRB members and chairs regarding investigators' relationships with industry. J Empir Res Hum Res Ethics 2008;3:3-13. [Web of Science][Medline]
13. Boyd EA, Lipton S, Bero LA. Implementation of financial disclosure policies to manage conflicts of interest. Health Aff (Millwood) 2004;23:206-214. [Free Full Text]
14. Weinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J. Views of potential research participants on financial conflicts of interest: barriers and opportunities for effective disclosure. J Gen Intern Med 2006;21:901-906. [Web of Science][Medline]
15. Appelbaum PS, Roth LH, Lidz C. The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 1982;5:319-329. [CrossRef][Web of Science][Medline]
16. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;17:20-24. [Medline]
17. Dresser R. The ubiquity and utility of the therapeutic misconception. Soc Philos Policy 2002;19:271-294. [CrossRef][Web of Science][Medline]
18. Friedman JY, Sugarman J, Dhillon JK, et al. Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. Clin Trials 2007;4:272-278. [Free Full Text]
19. Weinfurt KP, Hall MA, Friedman JY, et al. Effects of disclosing financial interests on participation in medical research: a randomized vignette trial. Am Heart J 2008;156:689-697. [CrossRef][Web of Science][Medline]
20. Kim SY, Millard RW, Nisbet P, Cox C, Caine ED. Potential research participants' views regarding researcher and institutional conflicts of interest. J Med Ethics 2004;30:73-79. [Free Full Text]
21. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ. Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med 2006;355:2330-2337. [Free Full Text]
22. Grady C, Horstmann E, Sussman JS, Hull SC. The limits of disclosure: what research subjects want to know about investigator financial interests. J Law Med Ethics 2006;34:592-599. [Free Full Text]
23. Weinfurt KP, Hall MA, Dinan MA, et al. Effects of disclosing financial interests on attitudes toward clinical research. J Gen Intern Med 2008;23:860-866. [CrossRef][Web of Science][Medline]
24. Faden RR, Beauchamp TL. A history and theory of informed consent. New York: Oxford University Press, 1986.
25. Hall MA, Bobinski MA, Orentlicher D. Health care law and ethics. 7th ed. New York: Aspen, 2007.
26. Kass NE, Sugarman J, Faden R, Schoch-Spana M. Trust, the fragile foundation of contemporary biomedical research. Hastings Cent Rep 1996;26:25-29. [Web of Science][Medline]
27. Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q 2001;79:613-639. [CrossRef][Web of Science][Medline]
28. Hall MA, Dugan E, Balkrishnan R, Bradley D. How disclosing HMO physician incentives affects trust. Health Aff (Millwood) 2002;21:197-206. [Free Full Text]
29. Coleman CH. Duties to subjects in clinical research. Vanderbilt Law Rev 2005;58:387-420.
30. Resnik DB. Disclosing conflicts of interest to research subjects: an ethical and legal analysis. Account Res 2004;11:141-159. [Medline]
31. Morreim EH. The clinical investigator as fiduciary: discarding a misguided idea. J Law Med Ethics 2005;33:586-598. [Free Full Text]
32. Sage WM. Some principles require principals: why banning conflicts of interest won't solve incentive problems in biomedical research. Tex Law Rev 2007;85:1113-1163.
33. Wilson RF. Money, prestige, and conflicts of interests in human subjects research. New York: Aspen, 2009.
34. Hall MA, Berenson RA. Ethical practice in managed care: a dose of realism. Ann Intern Med 1998;128:395-402. [Free Full Text]
35. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-255. [Free Full Text]
36. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud 2005;34:1-25. [CrossRef][Web of Science]
37. Capron AM. Informed consent in catastrophic disease research and treatment. Univ PA Law Rev 1974;123:340-438. [Medline]
38. Report to the Congress: Medicare payment policy. Washington, DC: Medicare Payment Advisory Commission (MedPAC), March 2009. (Accessed August 6, 2009, at
http://www.medpac.gov/documents/Mar09_EntireReport.pdf.)
39. Report to the Congress: reforming the delivery system. Washington, DC: Medicare Payment Advisory Commission (MedPAC), June 2008. (Accessed August 6, 2009, at
http://www.medpac.gov/documents/Jun08_EntireReport.pdf.)
40. Ehringhaus SH, Weissman JS, Sears JL, Goold SD, Feibelmann S, Campbell EG. Responses of medical schools to institutional conflicts of interest. JAMA 2008;299:665-671. [Free Full Text]
41. Stossel TP. Regulating academic-industrial research relationships -- solving problems or stifling progress? N Engl J Med 2005;353:1060-1065. [Free Full Text]
42. Fisher MA. Medicine and industry: a necessary but conflicted relationship. Perspect Biol Med 2007;50:1-6. [Web of Science][Medline]
43. Krimsky S. Introduction to special issue of Accountability in Research on conflict of interest in science. Account Res 2004;11:79-81. [Medline]
